Edit concept Question Editor Create issue ticket




  • In the present case, amrinone improved pulmonary hypertension, oxygenation and CO 2 elimination probably via direct pulmonary vasodilatation.[jstage.jst.go.jp]
  • This work has been presented in part previously in the following abstracts: Xiong W, Ferrier GR, and Howlett SE (1998) Amrinone potentiates contractions initiated by a voltage sensitive mechanism in ventricular myocytes from normal but not cardiomyopathic[doi.org]
  • This new third edition presents an in-depth discussion of: All cardiovascular agents currently available The scientific basis behind every pharmacotherapy advance Mechanisms of action of cardiovascular pharmacotherapeutics The latest advances in cardiovascular[books.google.com]
  • PDE III is present in cardiac muscle, vascular smooth muscle and platelets. PDE III degrades the phosphodiester bond in cAMP to break it down. When PDE III is inhibited, cAMP cannot be inactivated.[en.wikipedia.org]
  • The CLP Regulation makes sure that the hazards presented by chemicals are clearly communicated to workers and consumers in the European Union.[echa.europa.eu]
Intravenous Administration
  • Acute intravenous administration caused a significant reduction in mean blood pressure and this was severe enough to require correction by plasma infusion in five patients.[heart.bmj.com]
  • Currently, only acute intravenous administration takes place. The effects of amrinone vary widely with species and experimental condition; therefore inotropic effects are variable.[en.wikipedia.org]
  • Nesiritide is given by intravenous administration. It is used in decompensated congestive heart failure to produce a rapid decrease in peripheral vascular resistance and blood pressure.[uky.edu]
  • Thrombocytopenia is the most prominent and dose-related side effect, but it is transient and asymptomatic. Nausea, diarrhoea, hepatotoxicity, arrhythmias and fever are other adverse effects. IV bolus and infusion as described earlier.[en.wikipedia.org]
  • Some serious side effects of long term administration included sustained ventricular tachycardia resulting in circulatory collapse, worsening myocardial ischemia, acute myocardial infarction, and worsening congestive heart failure.[en.wikipedia.org]
Left Ventricular Dysfunction
  • Progression of left ventricular dysfunction was associated with a progressive increase in heart rate and plasma renin activity and a decline in serum sodium concentration.[doi.org]
  • Wallenhaupt, “Amrinone in Cardiac Surgical Patients with Left Ventricular Dysfunction. A Prospective, Randomized Placeo-Controlled Trial,” Chest, Vol. 104, No. 6, 1993, pp. 1660-1667. doi:10.1378/chest.104.6.1660 [ 13 ] M. Gillies, R. Bellomo, L.[scirp.org]
  • Amrinone in cardiac surgical patients with left-ventricular dysfunction. Chest 1993;104:1660-7. 6. Butterworth JF IV, Hines RL, Royster RL, James RL. A pharmacokinetic and pharmacodynamic evaluation of milrinone in adults undergoing cardiac surgery.[journals.lww.com]
  • Adverse Effects Thrombocytopenia (2-3%) Occurs within 48-72 hours Resolves after discontinuing Amrinone Dose dependent effect Nausea and Vomiting Myalgia Fever Hepatic dysfunction Arrhythmia Ventricular irritability X.[fpnotebook.com]
  • To verify favourable long-term effects, 14 patients with chronic congestive heart failure, NYHA class II-IV, who had been treated with oral amrinone for 8-15 months with apparent clinical benefit, had the drug withdrawn according to a 12 week placebo[ncbi.nlm.nih.gov]
  • Half life 5 to 8 hours Clearance Not Available Toxicity Not Available Affected organisms Humans and other mammals Pathways Not Available Pharmacogenomic Effects/ADRs Not Available Drug Interactions All Drugs Approved Vet approved Nutraceutical Illicit Withdrawn[drugbank.ca]


  • ., 2002, Modulation of TNF and GM-CSF release from dispersed human nasal polyp cells and human whole blood by inhibitors of different PDE isoenzymes and glucocorticoids., Pulm Pharmacol Ther Kumar et al., 1999, Effects of epinephrine and amrinone on contractility[dgidb.org]
  • J Pharmacol Exp Ther. 2002 Feb;300(2):559-66. [ PubMed:11805217 ] Marx D, Tassabehji M, Heer S, Huttenbrink KB, Szelenyi I: Modulation of TNF and GM-CSF release from dispersed human nasal polyp cells and human whole blood by inhibitors of different PDE[drugbank.ca]


  • Ten patients died during the first 2 weeks of treatment, and 16 (52%) were dead within 3 months, a mortality rate twice as great as that seen during comparable trials with vasodilating drugs.[doi.org]
  • Pharmacology and Therapeutics for Dentistry, 6th Edition describes how to evaluate a patient’s health and optimize dental treatment by factoring in the drugs they take.[books.google.de]
  • Not recommended in acute MI treatment. Monitor fluid status closely; patients may require adjustment of diuretic and electrolyte replacement therapy. Can cause thrombocytopenia (dose-dependent). Correct hypokalemia before initiating therapy.[syrianclinic.com]
  • A licensed medical professional should be consulted for diagnosis and treatment of any and all medical conditions. Call 911 for all medical emergencies.[centurahealthinfo.org]


  • NEWS HIGHLIGHTS Media Articles Related to Inamrinone Congestive Heart Failure (CHF) Symptoms, Stages, and Prognosis Source: MedicineNet Amyloidosis Specialty [2017.08.11] Title: Congestive Heart Failure (CHF) Symptoms, Stages, and Prognosis Category:[druglib.com]
  • It is a drug that may improve the prognosis in patients with congestive heart failure. Amrinone has been shown to increase the contractions initiated in the heart by high gain calcium induced calcium release (CICR).[symcat.com]


  • There are several forms of heart failure with multiple etiologies.[uky.edu]


  • The presence of an antagonist might also up-regulate the beta 1 receptor that have been down-regulated by the pathophysiology of heart failure. One pathophysiology of heart failure is that the heart increases dimensions.[uky.edu]


  • Amrinone (INN) or inamrinone (USAN, changed in 2000 to prevent confusion with amiodarone), trade name Inocor, is a pyridine phosphodiesterase 3 inhibitor. It is a drug that may improve the prognosis in patients with congestive heart failure.[symcat.com]
  • […] drug therapy Specific drug treatments, and information on recently approved drugs Molecular biological advances Drugs in development Hands-on discussions of how to utilize specific drugs for treatment of various cardiovascular disorders and for the prevention[books.google.com]
  • Inamrinone inhibits type III phosphodiesterase, which is abundant in cardiac and vascular tissues, thereby preventing the degradation of cyclic adenosine monophosphate (cAMP) and increasing intracellular concentrations of this secondary messenger.[fpnotebook.com]

Ask Question

5000 Characters left Format the text using: # Heading, **bold**, _italic_. HTML code is not allowed.
By publishing this question you agree to the TOS and Privacy policy.
• Use a precise title for your question.
• Ask a specific question and provide age, sex, symptoms, type and duration of treatment.
• Respect your own and other people's privacy, never post full names or contact information.
• Inappropriate questions will be deleted.
• In urgent cases contact a physician, visit a hospital or call an emergency service!